Canary’s First U.S. Injective Staking ETF Trades 2,933 Shares

Canary Capital’s Canary Staked INJ ETF began trading on Nasdaq Nov. 5, giving U.S. investors a listed vehicle for staking-focused exposure to Injective (INJ) as 2,933 shares changed hands on its first session.

The fund trades under ticker INJC. Its shares opened at $25.15, reached an intraday high of $26.45 and closed at about $26.15. The launch marked the first U.S.-listed ETF focused on staking INJ.

Under normal conditions, the fund aims to stake at least 90% of its INJ holdings, leaving the balance available for redemptions. Rewards are added to daily net asset value rather than paid to shareholders as cash. The fund charges a 1.10% annual management fee and takes about 30% of staking rewards as fees.

The structure reflects Injective’s 21-day unstaking period, which prevents staked tokens from being unlocked immediately for redemptions. The listing gives U.S. brokerage and IRA account holders a way to access staking-based INJ exposure without managing wallets or private keys.